Company Hyloris Pharmaceuticals SA

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 11:35:03 2024-12-13 am EST			5-day change	1st Jan Change
5.900 ^EUR	-0.67%		+9.26%	-53.73%

Oct. 16	Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
Jul. 08	That's not so bad, is it?

Business description: Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.

Number of employees: 41

Sales by Activity: Hyloris Pharmaceuticals SA

Fiscal Period: December	2019	2020	2021	2022	2023
Pharmaceuticals	91K	175K	3.1M	2.95M	4.21M

See all business segments

Geographical breakdown of sales: Hyloris Pharmaceuticals SA

Fiscal Period: December	2019	2020	2021	2022	2023
United States	-	-	-	-	1.12M
Belgium	91K	175K	3.1M	2.95M	-

See all geographic segments

Managers: Hyloris Pharmaceuticals SA

Director	Title	Age	Since
Thomas Jacobsen CEO	Chief Executive Officer	50	-
Stijn van Rompay CEO	Chief Executive Officer	48	2011-12-31
Christophe Maréchal DFI	Director of Finance/CFO	-	2024-12-08
Dietmar Aichhorn COO	Chief Operating Officer	-	2020-09-30

See HYLORIS PHARMACEUTICALS SA governance

Members of the board: Hyloris Pharmaceuticals SA

Manager	Title	Age	Since
Stijn van Rompay BRD	Director/Board Member	48	2020-11-29
Thomas Jacobsen BRD	Director/Board Member	50	2011-12-31
Stefan Yee CHM	Chairman	62	2019-09-30
Marc Foidart BRD	Director/Board Member	-	2019-12-31
Carolyn Myers BRD	Director/Board Member	66	2019-12-31
James Gale BRD	Director/Board Member	74	2019-12-31
Chris Buyse BRD	Director/Board Member	59	2020-12-31

Composition of the Board of Directors

Shareholders: Hyloris Pharmaceuticals SA

Name	Equities	%	Valuation
Stijn van Rompay 27.42 %	7,676,400	27.42 %	43 M €
Thomas Jacobsen 13.06 %	3,657,505	13.06 %	20 M €
Bart Versluys 6.170 %	1,727,623	6.170 %	10 M €
Nick Reunbrouck 5.750 %	1,610,021	5.750 %	9 M €
Pieter van Rompay 3.270 %	915,612	3.270 %	5 M €

List of HYLORIS PHARMACEUTICALS SA shareholders

Company details: Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA

Boulevard Patience et Beaujonc N°3/1

4000, Liege

+32 4 346 02 07

http://www.hyloris.com

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
HYLORIS PHARMACEUTICALS SA	-0.67%	+9.26%	-49.14%	-65.19%	173M
ELI LILLY AND COMPANY	+0.87%	-4.55%	+32.07%	+217.51%	711B
NOVO NORDISK A/S	-3.89%	-4.01%	+12.24%	+97.87%	469B
JOHNSON & JOHNSON	+0.26%	-1.80%	-5.89%	-12.96%	353B
ABBVIE INC.	+0.10%	-1.60%	+12.36%	+37.04%	306B
MERCK & CO., INC.	+0.74%	-1.06%	-4.77%	+38.93%	258B
ROCHE HOLDING AG	-0.90%	-1.48%	+0.22%	-32.53%	228B
ASTRAZENECA PLC	-0.95%	-1.75%	+0.75%	+26.92%	205B
NOVARTIS AG	-0.36%	-2.30%	+1.19%	+17.71%	196B
AMGEN INC.	-1.26%	-0.72%	-3.91%	+28.02%	145B
Average	-0.79%	-0.94%	-0.49%	+35.33%	287.19B
Weighted average by Cap.	-0.71%	-2.67%	+10.05%	+77.64%